Heart failure
Conditions
Interventions
Standard-care group (Standard treatment without MUSKARDIA):None
MUSKARDIA group (Standard treatment augmented with MUSKARDIA):Medication (MUSKARDIA)
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Adults aged between 18 and 85 years; 2.Confirmed diagnosis of coronary heart disease via coronary angiography or computed tomography angiography (CTA); 3.Diagnosed with heart failure according to the criteria outlined in the "2024 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure," with a left ventricular ejection fraction (LVEF) greater than 45%; 4.New York Heart Association (NYHA) functional class II to IV; 5.N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels exceeding 600 pg/mL; for patients with concomitant atrial fibrillation, NT-proBNP must exceed 900 pg/mL; 6.Provision of signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Heart failure caused by non-cardiac origins such as valvular heart disease, congenital heart disease, pericardial disease, etc.; 2.Hospitalization for heart failure within the past 4 weeks; 3.Admission or cardiac surgery due to acute coronary syndrome within the past 4 weeks; 4.Coronary artery stenosis of less than 50% as shown by coronary angiography or CTA; 5.Uncontrolled hypertension (systolic blood pressure >=180 mmHg or diastolic blood pressure >=110 mmHg); 6.Severe hepatic, renal, or hematological disorders; 7.Pregnant or breastfeeding women; 8.Current use of MUSKARDIA or known allergy to it; 9.Uncontrolled psychiatric conditions or other systemic diseases; 10.Receipt of other investigational drug treatments within 30 days prior to randomization; 11.Inability to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Kansas City Cardiomyopathy Questionnaire (KCCQ) score;Echocardiographic indicators;Heart failure hospitalization;Cardiovascular mortality; | — |
Countries
China
Contacts
Public ContactChen Kangyu
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed